Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 20/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.76 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6762870 | 0.86 | SLC6A3 (1.00) | SLC6A3SLC6A4 | |
| SCHEMBL26683259 | 0.70 | SLC6A3 (0.60) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL26683256 | 0.70 | SLC6A3 (0.60) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL6767667 | 0.70 | SLC6A3 (0.76) | SLC6A3SLC6A4 | |
| SCHEMBL11239464 | 0.70 | SLC6A3 (0.53) | SLC6A3SLC6A4 | |
| SCHEMBL26683852 | 0.69 | SLC6A3 (1.00) | SLC6A3SLC6A4 | |
| SCHEMBL2286519 | 0.68 | SLC6A3 (0.56) | SLC6A3SLC6A4 | |
| SCHEMBL5409520 | 0.68 | SLC6A3 (0.78) | SLC6A3SLC6A4 | |
| SCHEMBL5409514 | 0.68 | SLC6A3 (0.78) | SLC6A3SLC6A4 | |
| SCHEMBL2900331 | 0.67 | SLC6A3 (0.49) | SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677338-B2 | FOR THERAPY OF DEPRESSION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2004-01-13 | — | — | US | disclosed |
| US-20030105096-A1 | Serotonin transport inhibitors | WILMINGTON TRUST (LONDON) LIMITED, AS SECURITY AGENT (GB) | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105096-A1 | Serotonin transport inhibitors | SLC6A4, SLC6A2, SLC18A2 | SLC6A3 4/4885SLC6A4 1/4885SLC6A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.